Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | FASN | P49327 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.37 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.37 |
| ▸ | USP30 | Q70CQ3 | 4/20 | 0.37 |
| ▸ | GRIA1 | P42261 | 3/20 | 0.36 |
| ▸ | LRRK2 | Q5S007 | 2/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | ATM | Q13315 | 1/20 | 0.36 |
| ▸ | NAMPT | P43490 | 1/20 | 0.35 |
| ▸ | SYK | P43405 | 1/20 | 0.35 |
| ▸ | NTSR1 | P30989 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL316367 | 0.80 | HPGD (0.45) | HPGDGRIA1NAMPT | |
| SCHEMBL24891365 | 0.78 | P2RY12 (0.46) | HPGDALDH1A1KDM4ESMN1; SMN2USP30 | |
| SCHEMBL316452 | 0.68 | PDE1B (0.33) | GRIA1SYKNTSR1 | |
| SCHEMBL3601247 | 0.67 | AR (0.57) | — | |
| SCHEMBL15676577 | 0.67 | NOTUM (0.42) | KDM4ESMN1; SMN2USP30 | |
| SCHEMBL30149942 | 0.67 | NOTUM (0.42) | KDM4ESMN1; SMN2USP30 | |
| SCHEMBL317654 | 0.66 | SMN1; SMN2 (0.46) | HPGDALDH1A1KDM4ESMN1; SMN2KMT2A | |
| SCHEMBL20073529 | 0.66 | TYK2 (0.42) | FASNUSP30 | |
| Nitrogen SCHEMBL11221729 | 0.66 | USP30 (0.43) | USP30NTSR1 | |
| SCHEMBL13486520 | 0.65 | NOTUM (0.50) | USP30NTSR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2081903-B1 | 2-AMINOCARBONYL-PYRIDINE DERIVATIVES | ACTELION PHARMACEUTICALS LTD (CH) | 2014-05-07 | — | — | EP | disclosed |
| US-8093250-B2 | 2-aminocarbonyl-pyridine derivatives | ACTELION PHARMACEUTICALS LTD. (CH) | 2012-01-10 | — | — | US | disclosed |
| US-20100035895-A1 | 2-AMINOCARBONYL-PYRIDINE DERIVATIVES | ACTELION PHARMACEUTICALS LTD. (CH) | 2010-02-11 | — | — | US | disclosed |
| EP-2081903-A2 | 2-AMINOCARBONYL-PYRIDINE DERIVATIVES | Actelion Pharmaceuticals Ltd. (CH) | 2009-07-29 | — | — | EP | disclosed |
| WO-2008044217-A2 | 2-AMINOCARBONYL-PYRIDINE DERIVATIVES | ACTELION PHARMACEUTICALS LTD (CH) | 2008-04-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100035895-A1 | 2-AMINOCARBONYL-PYRIDINE DERIVATIVES | P2RY12, P2RY2, P2RY1 | HPGD 1203/4885ALDH1A1 978/4885KDM4E 3164/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.